Medical News

RSS

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Researchers produce artificial antibody capable of blocking prions in the laboratory

Prion diseases affect the brain, causing neurodegenerative problems that always lead to death. They attracted attention in the late 1990s due to the "Mad Cow" scare.

22 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

Educational initiatives needed to improve knowledge about biosimilars in oncology

Biological medicines are responsible for some of the most promising innovations in cancer treatment, including immunotherapy, targeted drugs and vaccines - but they are also expensive.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

At-home biofeedback therapy effective in relieving difficult-to-treat constipation

Biofeedback therapy used at home is about 70 percent effective at helping patients learn how to coordinate and relax bowel muscles and relieve one of the most difficult-to-treat types of constipation, investigators report.

22 Oct 2018

Canon Medical to showcase world's first Ultra-High Resolution CT system at ASTRO 2018

At this year's American Society of Radiation Oncology (ASTRO) annual meeting in San Antonio, Texas, October 21-24, 2018 (Booth #3737), Canon Medical Systems USA, Inc. will showcase its recently FDA-cleared Aquilion PrecisionTM, the world's first Ultra-High Resolution CT system.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents

New research suggests that rising childhood obesity rates are causing more adolescents to develop a debilitating hip disease requiring urgent surgery.

22 Oct 2018

Free phone app helps low-income obese patients to lose weight

With the help of a free phone app, low-income obese patients with signs of cardiovascular risk lost a clinically meaningful amount of weight, finds new research from Duke University.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New 3D bioprinting technique shows potential for artificial tissue fabrication

University of Colorado Boulder engineers have developed a 3D printing technique that allows for localized control of an object's firmness, opening up new biomedical avenues that could one day include artificial arteries and organ tissue.

22 Oct 2018

HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study

A new study reveals that Hispanic HIV-infected adults in the United States are at a higher risk of developing cancers caused by the human papillomavirus than Hispanics from the general population.

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease, according to results from a pre-planned analysis of a large comparison study reported at ESMO 2018.

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Medical News

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Researchers produce artificial antibody capable of blocking prions in the laboratory

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Educational initiatives needed to improve knowledge about biosimilars in oncology

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

At-home biofeedback therapy effective in relieving difficult-to-treat constipation

Canon Medical to showcase world's first Ultra-High Resolution CT system at ASTRO 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents

Free phone app helps low-income obese patients to lose weight

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New 3D bioprinting technique shows potential for artificial tissue fabrication

HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News